The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation.
Tryptophan metabolites, including kynurenine, 3-hydroxyanthranilic acid, and picolinic acid, are key mediators of immunosuppression by cells expressing the tryptophan-catabolizing enzyme indoleamine2,3-dioxygenase. In this study, we assessed the influence of picolinic acid on cell viability and effector functions of CD4(+)T cells following in vitro activation with agonistic anti-CD3/anti-CD28 antibodies. In contrast to kynurenine and 3-hydroxyanthranilic acid, exposure of T cells with picolinic acid did not affect cell viability, whereas proliferation and metabolic activity were suppressed in a dose-dependent manner. On the other hand, cytokine secretion and up-regulation of cell surface activation markers were not or only weakly inhibited by picolinic acid. Picolinic acid exposure induced a state of deep anergy that could not be overcome by the addition of exogenous IL-2 and inhibited Th cell polarization. On the molecular level, important upstream signaling molecules, such as the MAPKs ERK and p38 and the mammalian target of rapamycin target protein S6 ribosomal protein, were not affected by picolinic acid. Likewise, NFAT, NF-κB, and AP-1 promoter activity in Jurkat T cells was not influenced by exposure to picolinic acid. Whereas transcriptional levels of v-myc avian myelocytomatosis viral oncogene homolog were not affected by picolinic acid, phosphorylation at Ser62 was strongly reduced in picolinic acid-exposed T cells following activation. In conclusion, picolinic acid mediates a unique immunosuppressive program in T cells, mainly inhibiting cell cycle and metabolic activity, while leaving other effector functions intact. These functional features are accompanied by reduced phosphorylation of v-myc avian myelocytomatosis viral oncogene homolog. It remains to be determined whether this effect is mediated by direct inhibition of ERK activity or whether indirect mechanisms apply.
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Johanna
J
Prodinger
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Lisa J
LJ
Loacker
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Ralf L J
RL
Schmidt
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Franz
F
Ratzinger
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Georg
G
Greiner
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Nadine
N
Witzeneder
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Gregor
G
Hoermann
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Sabrina
S
Jutz
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Winfried F
WF
Pickl
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Peter
P
Steinberger
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Rodrig
R
Marculescu
*Department of Laboratory Medicine and Institute of Immunology, Medical University of Vienna, Vienna, Austria klaus.schmetterer@meduniwien.ac.at.
Klaus G
KG
Schmetterer
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation / Q000187:drug effects*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000276:immunology; D006801:Humans; D019169:Jurkat Cells; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D010848:Picolinic Acids / Q000494:pharmacology*; D016271:Proto-Oncogene Proteins c-myc / Q000276:immunology*; D014157:Transcription Factors / Q000276:immunology
C489427:MYC protein, human; D010848:Picolinic Acids; D016271:Proto-Oncogene Proteins c-myc; D014157:Transcription Factors; D048049:Extracellular Signal-Regulated MAP Kinases; C030614:picolinic acid
anergy; immune tolerance; immunosuppression; indoleamine 2,3-dioxygenase